Breath-synchronized plume-control inhaler for pulmonary delivery of fluticasone propionate

International Journal of Pharmaceutics

Volumn 356, Issue 1-2, 2008, Pages 137-143

  Shrewsbury, Stephen B ^a   Armer, Thomas A ^a   Newman, Stephen P ^b   Pitcairn, Gary ^b  

^a MAP Pharmaceuticals Inc   (United States)

^b PHARMACEUTICAL PROFILES LTD   (United Kingdom)

Author keywords

Aerosol drug delivery; Breath synchronized plume control inhaler; Fluticasone propionate; Lung deposition

Indexed keywords

FLUTICASONE PROPIONATE; TECHNETIUM 99M;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SCINTIGRAPHY; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INHALATION; ADULT; AEROSOLS; ANDROSTADIENES; ASTHMA; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; FEMALE; HUMANS; LUNG; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; RADIONUCLIDE IMAGING; TISSUE DISTRIBUTION;

EID: 42649131701     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.01.011     Document Type: Article

References (21)

1. Armer T.A., Shrewsbury S.B., Newman S.P., Pitcairn G., and Ramadan N. Aerosol delivery of ergotamine tartrate via a breathsynchronized plume-control inhaler in humans. Curr. Med. Res. Opin. 23 (2007) 3177-3187
2. Barnes P.J., Pedersen S., and Busse W.W. Efficacy and safety of inhaled corticosteroids. New developments. Am. J. Resp. Crit. Care Med. 157 (1998) S1-S53
3. Bisgaard H., Anhoj J., and Wildhaber J.H. Spacer devices. In: Bisgaard H., O'Callaghan C., and Smaldone G.C. (Eds). Drug Delivery to the Lung (2002), Marcel Dekker, New York 389-420
4. Borgström L., Olsson B., and Thorsson L. Degree of throat deposition can explain the variability in lung deposition of inhaled drugs. J. Aerosol. Med. 19 (2006) 473-483
5. Borgström L., Bengtsson T., Derom E., and Pauwels R. Variability in lung deposition of inhaled drug, within and between asthmatic patients, with a pMDI and a dry powder inhaler. Turbuhaler. Int. J. Pharm. 193 (2000) 227-230
6. Brocklebank D., Ram R., Wright J., Barry P., Cates C., Davies L., Douglas G., Muers M., Smith D., and White J. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol. Assess. 5 (2001) 1-149
7. Cerasoli F. Developing the ideal inhaled corticosteroid. Chest 130 (2006) 54S-64S
8. Derendorf H., Nave R., Drollmann A., Cerasoli F., and Wurst W. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur. Respir. J. 28 (2006) 1042-1050
9. Dunbar C., and Mitchell J. Analysis of cascade impactor mass distributions. J. Aerosol. Med. 18 (2005) 439-451
10. Hampson N.B., and Mueller M.P. Reduction in patient timing errors using a breath-activated metered dose inhaler. Chest 106 (1994) 462-465
11. Newman S.P. Principles of metered-dose inhaler design. Respir. Care 50 (2005) 1177-1190
12. Newman S.P., Clark A.R., Talaee N., and Clarke S.W. Pressurised aerosol deposition in the human lung with and without an "open" spacer. Thorax 44 (1989) 706-710
13. Newman S.P., Pitcairn G.R., Hirst P.H., and Rankin L. Radionuclide imaging technologies and their use in evaluating asthma drug. Adv. Drug. Deliv. Rev. 55 (2003) 851-867
14. Newman S.P., Weisz A.W.B., Talaee N., and Clarke S.W. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax 46 (1991) 712-716
15. Newman S.P., Wilding I.R., and Hirst P.H. Human lung deposition data: the bridge between in vitro and clinical evaluations for inhaled drug products?. Int. J. Pharm. 208 (2000) 49-60
16. Pauwels R., Newman S., and Borgstrom L. Airway deposition and airway effects of antiasthma drugs delivered from metered-dose inhalers. Eur. Resp. J. 10 (1997) 2127-2138
17. Pitcairn G.R., and Newman S.P. Tissue attenuation corrections in gamma scintigraphy. J. Aerosol. Med. 10 (1997) 187-198
18. Price D., Thomas M., Mitchell G., Niziol C., and Featherstone R. Improvement of asthma control with a breath-actuated pressurized metered dose inhaler (BAI): a prescribing claims study of 5556 patients using a traditional pressurised metred dose inhaler (MDI) or a breath-actuated device. Respir. Med. 97 (2003) 12-19
19. Rau J.L. The inhalation of drugs: advantages and problems. Respir. Care 50 (2005) 367-382
20. Roland N.J., Bhalla R.K., and Earis J. The local side effects of inhaled corticosteroids. Current understanding and review of the literature. Chest 126 (2004) 213-219
21. Snell N.J.C., and Ganderton D. Assessing lung deposition of inhaled medications. Consensus statement from a workshop of the British Association for Lung Research, held at the Institute of Biology, London, UK on 17 April 1998. Respir. Med. 93 (1999) 123-133